NCT02343549 2022-11-03
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
Phase 2 Terminated
Wake Forest University Health Sciences
H. Lee Moffitt Cancer Center and Research Institute
FDA Office of Orphan Products Development
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute